Cullinan Therapeutics, Inc. (CGEM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CGEM currently has 60.5M outstanding shares. with significant dilution risk as 39.1M authorized shares could dilute existing holders by 64.6%. The company has diluted shareholders by 18.19% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 60.5M shares outstanding |
60M | 39M |
| Mar 10, 2026 |
10-K filing | 59.1M shares outstanding |
59M | 39M |
| Nov 06, 2025 |
10-Q filing | 59.1M shares outstanding |
59M | 39M |
| Aug 07, 2025 |
10-Q filing | 59.0M shares outstanding |
59M | 39M |
| May 08, 2025 |
10-Q filing | 58.9M shares outstanding |
59M | 39M |
| Feb 27, 2025 |
10-K filing | 53.8M shares outstanding |
54M | 39M |
| Nov 07, 2024 |
10-Q filing | 58.3M shares outstanding |
58M | 39M |
| Aug 08, 2024 |
10-Q filing | 55.1M shares outstanding |
55M | 39M |
| May 16, 2024 |
S-3 filing: This S-3 filing relates to the disposition of up to 14,421,070 shares of common stock and up to 315,790 shares of common stock issuable upon the exercise of pre-funded warrants by selling stockholders. |
58M | 39M |
| May 15, 2024 |
10-Q filing | 57.6M shares outstanding |
58M | 24M |
| Apr 16, 2024 |
8-K filing: Cullinan Therapeutics, Inc. entered into a Stock Purchase Agreement for a private placement of 14,421,070 shares of common stock at $19.00 per share and 315,790 pre-funded warrants at $18.999 per Pre-Funded Warrant, with gross proceeds expected to be approximately $280 million before deducting fees. The company also changed its name from Cullinan Oncology, Inc. ($280.0M proceeds) |
42M | 24M |
| Mar 14, 2024 |
10-K filing | 41.6M shares outstanding |
42M | 24M |
| Nov 08, 2023 |
10-Q filing | 42.7M shares outstanding |
43M | 24M |
| Aug 10, 2023 |
10-Q filing | 40.0M shares outstanding |
40M | 24M |
| May 11, 2023 |
S-3/A filing: Cullinan Oncology, Inc. is filing an S-3/A form to offer and sell debt securities, common stock, preferred stock, depositary shares, subscription rights, and purchase contracts from time to time in one or more offerings of up to $350,000,000 in aggregate offering price. |
39M | 24M |
| May 11, 2023 |
10-Q filing | 40.7M shares outstanding |
41M | 24M |
| Mar 09, 2023 |
10-K filing | 39.3M shares outstanding |
39M | 12M |
| Mar 09, 2023 |
S-3 filing: Cullinan Oncology, Inc. may offer and sell securities from time to time in one or more offerings of up to $350,000,000 in aggregate offering price. |
46M | 12M |
| Nov 14, 2022 |
10-Q filing | 45.6M shares outstanding |
46M | 12M |
| Aug 10, 2022 |
10-Q filing | 44.9M shares outstanding |
45M | 12M |
| May 16, 2022 |
10-Q filing | 44.8M shares outstanding |
45M | 12M |
| Mar 17, 2022 |
10-K filing | 44.6M shares outstanding |
45M | 12M |
| Nov 09, 2021 |
10-Q filing | 43.7M shares outstanding |
44M | 12M |
| Aug 10, 2021 |
10-Q filing | 43.5M shares outstanding |
44M | 12M |
| May 14, 2021 |
10-Q filing | 43.5M shares outstanding |
44M | 12M |
| Jan 06, 2021 |
S-1/A filing: The filing is an S-1/A registration statement for a company offering 10,000,000 shares of common stock, with an option for underwriters to purchase an additional 1,500,000 shares. |
39M | 12M |
| Jan 04, 2021 |
S-1/A filing: This S-1/A filing details the terms of common stock, including voting rights, dividend entitlements, and liquidation preferences. It also describes the authorization for the board of directors to issue up to 10,000,000 shares of convertible preferred stock and registration rights agreement with certain shareholders. |
N/A | 0 |